<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972487</url>
  </required_header>
  <id_info>
    <org_study_id>Expanded Access for Tofersen</org_study_id>
    <nct_id>NCT04972487</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis</brief_title>
  <official_title>Expanded Access Program (EAP) for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis (SOD1-ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      The objective is to provide access to tofersen to participants with SOD1-ALS with the most&#xD;
      rapidly progressive disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Superoxide Dismutase 1-Amyotropic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofersen</intervention_name>
    <description>Administered as intrathecal bolus injection</description>
    <other_name>BIIB067</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Medically able to undergo the program procedures, as determined by the treating&#xD;
             healthcare professional (HCP).&#xD;
&#xD;
          -  Weakness attributable to ALS and associated with a mutation in the SOD1 gene&#xD;
             (SOD1-ALS).&#xD;
&#xD;
          -  Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) decline&#xD;
             faster than 2.0 points per month (points/month) at most recent assessment, with slope&#xD;
             calculated as: [(48) - (ALSFRS-R score at entry)] / [months since symptom onset].&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current participation in a clinical trial of tofersen.&#xD;
&#xD;
          -  Use of an investigational medicinal product (IMP) for amyotrophic lateral sclerosis&#xD;
             (ALS) within 5 half-lives of the IMP before the first dose of tofersen.&#xD;
&#xD;
          -  Participant's primary place of residence is outside of the country of treatment.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

